← Back to Search

Unknown

MRC375 150mg for Rheumatoid Arthritis

Phase 2
Waitlist Available
Research Sponsored by Molecular Research Center, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥4 tender joints/painful (28 joint count) at screening
≥4 swollen joints (28 joint count) at screening
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Study Summary

This study will treat moderate to severe rheumatoid arthritis with MRC375 (either 75 mg 3 times a day, 150 mg 3 times a day or placebo 3 times a day)in patients 18 years of age or older that can be currently on low doses of methotrexate or can stop treatment of current RA medications to enter the study. Safety of MRC375 will also be evaluated. There are up to 8 clinic visits over 24 weeks.

Eligible Conditions
  • Rheumatoid Arthritis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy evaluated of both doses of MRC375 compared to placebo after 24 weeks of treatment as measured by the rate of achievement of 20% improvement in ACR criteria
Secondary outcome measures
Compare the Efficacy of two doses of MRC375 when compared to a placebo for the change from baseline screening in each of the individual ACR components measuring RA after 24 weeks of treatment
Safety and tolerability of both doses of MRC375

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: MRC375 75 mgExperimental Treatment1 Intervention
MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
Group II: MRC375 150mgExperimental Treatment1 Intervention
MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
Group III: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Bilcare Global Clinical SuppliesUNKNOWN
Harrison Clinical ResearchIndustry Sponsor
5 Previous Clinical Trials
1,104 Total Patients Enrolled
BARC Global Central LaboratoryUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
2011. "A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01408602.
All > Rheumatoid Arthritis > Ra
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top